A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter study of the Analgesic Efficacy and Safety Of A Dose Titration Regimen For The Subcutaneous Administration Of Tanezumab In Subjects with Osteoarthritis Of The Hip Or Knee
This is A randomized, double-blind, placebo-controlled, multicenter, parallel-group, study of the efficacy and safety of Tanezumab when administered by SC injection for 16 weeks compared to placebo in subjects osteoarthritis of the Knee or hip. Subjects will receive a total of two injections, separated by 8 weeks.
For more information contact Christina Stahl at 615-835-4750 or by email at cstahl@qualitymedicalresearch.com
Condition | Arthritis and Arthritic Pain, Osteoarthritis |
---|---|
Clinical Study Identifier | TX145055 |
Sponsor | Pfizer |
Last Modified on | 23 November 2020 |
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.